Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vyome Holdings, Inc. - Common Stock (NQ:HIND)

1.999 +0.039 (+1.99%)
Streaming Delayed Price Updated: 1:22 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vyome Holdings, Inc. - Common Stock

News headline image
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
From Vyome Holdings, Inc.
Via Business Wire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
From Vyome Holdings, Inc.
Via Business Wire
Top movers analysis one hour before the close of the markets on 2026-01-28: top gainers and losers in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Top movers in Wednesday's pre-market session ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
From Vyome Holdings, Inc.
Via Business Wire
News headline image
Vyome Holdings Announces Results of Annual Shareholder Meeting
From Vyome Holdings, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.